Kazia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 19, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Cap	139	10	8	26	58	130
Market Cap Growth	3145.93%	33.31%	-71.23%	-54.61%	-55.23%	305.89%
Enterprise Value	97.26	7.29	6.5	22.96	53.2	109.48
Last Close Price	12.13	6.27	11.43	58.00	210.00	493.00
PS Ratio	113.33	8.43	4.59	39699.80	3379.63	11.43
PB Ratio	4.59	-1.86	-1.14	3.29	4.62	4.59
P/TBV Ratio	0.55	-0.83	-0.60	1.77	3.04	3.07
EV/Sales Ratio	76.80	6.06	3.93	34458.70	3085.19	9.62
Debt / Equity Ratio	0.04	0	0	0	0	0
Net Debt / Equity Ratio	-0.66	0.48	0.10	-0.29	-0.30	-0.73
Net Debt / EBITDA Ratio	1.72	0.15	0.04	0.16	0.24	5.40
Net Debt / FCF Ratio	1.69	0.30	0.11	0.23	0.24	3.03
Asset Turnover	0.02	0.13	0.10	0.00	0.00	0.37
Quick Ratio	7.44	0.32	0.22	1.21	1.11	3.32
Current Ratio	8.61	0.35	0.24	1.42	1.40	3.53
Return on Equity (ROE)	-38.57%	226.01%	-2634.60%	-134.97%	-89.14%	-32.40%
Return on Assets (ROA)	-34.00%	-184.12%	-113.46%	-74.50%	-53.24%	-14.86%
Return on Invested Capital (ROIC)	-91.92%	1184.55%	-252.48%	-112.87%	-100.59%	-33.54%
Return on Capital Employed (ROCE)	-37.88%	452.19%	-349.08%	-97.20%	-64.33%	-18.82%
Buyback Yield / Dilution	-213.01%	-107.81%	-43.08%	-39.12%	-12.57%	-61.08%
Total Shareholder Return	-213.01%	-107.81%	-43.08%	-39.12%	-12.57%	-61.08%

Updated Mar 22, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q